Please login to the form below

Not currently logged in
Email:
Password:

Lucid Group names Neil Flash chief commercial officer

Flash joins the team from dna Communications

Neil Flash

Lucid Group has appointed Neil Flash as its new chief commercial officer, who joins from dna Communications.

In his previous role at dna, Flash served as EMEA managing director for six years. As managing director, he was responsible for the company’s brand proposition across the EMEA region, as well as the expansion of its client partner portfolio.

Prior to joining dna, he spent over five years at each of Huntsworth Health, Virgo and Cohn & Wolfe.

Flash has spent much of his career working for a number of major pharmaceutical and life sciences companies.

He has represented brands across each stage of the lifecycle, helping client partners to navigate the evolving healthcare sector across the UK, EMEA, Asia Pacific and global locations.

In addition to his career experience, Flash has a scientific background gained from a degree in BioMedical Science from Portsmouth University.

He has also been part of numerous award-winning teams, including those which have won agency award from Communiqué, Holmes Report and PRWeek. In addition, he has worked on award-winning campaigns recognised by Communiqué, PM Society and PR Week, and is a regular Communiqué judge.

“Neil is an exceptional communications professional and a talent we have admired for some time. His balance of commercial strategy, business and people focus make him a perfect fit for Lucid as he leads a core part of our business,” said Dennis O’Brien, Lucid Group CEO.

Article by
Lucy Parsons

22nd January 2020

From: Marketing

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...